Voydeya Shortage Update: What Patients Need to Know in 2026

If you've searched online to find out whether Voydeya (danicopan) is in shortage and found confusing or conflicting information, you're not alone. The access situation for Voydeya in 2026 is unusual: it is not on the FDA's drug shortage list, yet many PNH patients report significant difficulties getting it in a timely manner. This article explains what's actually going on — and what it means for you.

Is Voydeya in Shortage in 2026?

Short answer: No, Voydeya is not on the FDA official drug shortage list as of 2026. Alexion Pharmaceuticals has not reported manufacturing disruptions or supply chain problems for danicopan. However, "not in shortage" does not mean "easy to get" — and for Voydeya patients, access barriers are very real.

Why Do Patients Report Access Problems If There's No Shortage?

Voydeya's access challenges in 2026 fall into four main categories:

REMS Program Requirements. The VOYDEYA REMS mandates prescriber certification, patient vaccination, and certified pharmacy dispensing. Any gap in these requirements creates a delay before the medication can even be prescribed or dispensed.

Prior Authorization Bottlenecks. Because Voydeya costs $50,000–$100,000 per year, all major insurers require prior authorization. Incomplete submissions or payer-specific criteria differences can push approval timelines to 30+ days.

Single Specialty Pharmacy. Voydeya can only be dispensed through Onco360. This sole-source arrangement means all prescriptions funnel through one pharmacy, and while Onco360 has national reach, the coordination overhead can be significant.

Vaccine Timing Requirements. Patients must complete meningococcal and pneumococcal vaccinations at least 2 weeks before taking their first dose. If patients aren't vaccinated when their prescription is written, this adds 2+ more weeks to the access timeline.

Voydeya Background: A New Drug with Growing Access Channels

Voydeya was approved by the FDA on March 29, 2024, making it a relatively new medication. As a first-in-class oral Factor D inhibitor for PNH with EVH, it targets a specific subset of PNH patients — approximately 10–20% of those already on C5 inhibitors who continue to experience clinically significant extravascular hemolysis. Because the patient population is small and defined, the supply chain is designed around specialty pharmacy delivery rather than broad retail distribution.

What the Pivotal ALPHA Trial Showed

The ALPHA trial (ALXN2040-PNH-301) — the Phase 3 clinical study on which FDA approval was based — enrolled 84 subjects with PNH who had clinically significant EVH despite C5 inhibitor treatment. Patients randomized to Voydeya showed significant improvements in hemoglobin levels compared to placebo at 12 weeks, with many achieving hemoglobin levels in the normal range and experiencing fewer transfusions. This evidence base helped establish Voydeya as the first oral add-on therapy specifically addressing EVH in PNH.

How Insurance Coverage for Voydeya Has Evolved

Since Voydeya's 2024 approval, most major payers have added it to their formularies, though typically on specialty or non-preferred tiers with prior authorization requirements. As of 2026:

UnitedHealthcare covers Voydeya with PA through OptumRx — dispense exclusively through Onco360

Blue Cross Blue Shield plans typically require non-formulary exception requests with medical necessity documentation

Aetna CVS has designated Voydeya as available through CVS Specialty Pharmacy

Medicare Part D covers Voydeya — but government beneficiaries cannot use Alexion's commercial copay assistance program

What To Do If You're Having Trouble Getting Voydeya

Here are the most important steps to take right now if access is delayed:

Call Alexion OneSource (1-888-765-4747). This is the fastest first step — they handle PA support, REMS enrollment, and financial assistance.

Get vaccinated immediately. Do not wait. Getting the required meningococcal and pneumococcal vaccines now removes a major bottleneck from the timeline.

Ask your hematologist to file a PA immediately. The sooner the submission goes in, the sooner you can get a decision. Provide all lab documentation upfront to prevent delays.

If denied, appeal immediately. Many first-time PA denials for Voydeya are overturned on appeal. Your hematologist can request a peer-to-peer review with the insurance medical director.

The Bottom Line on Voydeya Access in 2026

Voydeya is not in shortage, but it is hard to access — and for PNH patients who need it, that distinction barely matters. If you're struggling to get your prescription, use every resource available: Alexion OneSource, your hematologist's office, and medfinder.com to help navigate access. For a step-by-step access guide, see our article on how to find Voydeya in stock near you.